ReviewAdvances in experimental medicine and biology2019
Current and Future Treatment of Helicobacter pylori Infections.
Review in Advances in experimental medicine and biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Penicillin Allergy Testing and Delabeling for Patients Who Are Prescribed Penicillin: A Systematic Review for a World Health Organization Guideline.Clinical reviews in allergy & immunology · 2024Pooled it
- Application of a semi-automatic, intensive follow-up for improving efficacy and adherence of Helicobacter pylori eradication therapy: A randomized controlled trial.MicrobiologyOpen · 2021Trial
- Article
- Article
- Lack of follow-up inWorld journal of gastroenterology · 2026Article
- Efficacy and safety of potassium-competitive acid blockers in eradicatingCaspian journal of internal medicine · 2026Review
- Design and Characterization of Novel Gastroretentive Drug Delivery System of Antibiotics and Piperine for the Eradication ofMolecular pharmaceutics · 2025Article
- Bicarinalin Enhances the Antibacterial Activity of Levofloxacin and Clarithromycin AgainstAntibiotics (Basel, Switzerland) · 2025Article
- The Controversies in the Relationship BetweenJournal of clinical medicine · 2025Review
- Multidisciplinary Approach Improves Eradication Rate and Safety in Refractory Helicobacter pylori Infection.Clinical and translational gastroenterology · 2025Article
- The efficacy and safety of Vonoprazan and Tegoprazan inTherapeutic advances in gastroenterology · 2025Article
- Efficacy of Sequential Metronidazole and Furazolidone with Proton Pump Inhibitors versus Standard Regimen in TreatingMedical journal of the Islamic Republic of Iran · 2025Article
- Breaking boundaries: the advancements in transdermal delivery of antibiotics.Drug delivery · 2024Review
- Vitamin B6 inhibits activity ofJournal of enzyme inhibition and medicinal chemistry · 2024Article
- Crises in Antimicrobial Stewardship: Misuse of Clarithromycin forPharmacoepidemiology · 2024Article
- The effects and mechanisms of natural products onFrontiers in cellular and infection microbiology · 2024Review
- Treatment ofHeliyon · 2023Review
- Anti-Helicobacter pylori activity of swertianolin, isolated from swertia herb.Journal of natural medicines · 2023Article
- Study of the Effect of Baicalin fromInternational journal of molecular sciences · 2023Article
- The Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy forAntibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Helicobacter pylori is one of the most common human pathogens and it has been estimated that about 50% of the world's population is currently infected. The present consensus is that, unless there are compelling reasons, all H. pylori infections should be cured. Since the 1990s, different national and international guidelines for the management of H. pylori-related diseases have been published and periodically updated regarding indications for treatment, diagnostic procedures, and preferred treatment regimens. Most guidelines provide sophisticated meta-analyses examining the outcome of different regimens done in regions with variable, often high rates of resistance to antibiotics, for which the prevalence and effects of resistance was often ignored. Although successful antimicrobial therapy must be susceptibility-based, increasing antimicrobial resistance and general unavailability of susceptibility testing have required clinicians to generally rely on empiric regimens. Antibiotics resistance of H. pylori has reached alarming high levels worldwide, which has an effect to efficacy of treatment. The recommendations should provide regimes for multi-resistant infections or for those where susceptibility testing is unavailable or refused. The first rule is to use only proven locally effective therapies. Because of patient intolerances, drug allergies, and local experiences, the clinicians should have at least two options for first-line therapy. As with any antimicrobial therapy, a thorough review of prior antibiotic use is invaluable to identify the presence of probably resistance. The second key is patient education regarding potential and expected side-effects and the importance of completing the course of antibiotics. We also review here triple therapies, sequential-concomitant, hybrid therapies, bismuth therapies, dual therapy, vonoprazan, modern antibiotic treatments, probiotics and vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.